MOTS-c for Sale — Buyer Guide 2026
MOTS-c is a mitochondrial-derived peptide studied for metabolic-regulation properties in preclinical research. Before purchasing from research vendors, verify batch-linked COAs confirming ≥98% purity via HPLC/MS, research-use-only labeling, and transparent third-party testing. MOTS-c is a regulated research compound — not an FDA-approved drug.
Midwest Peptide
10% off with code SQUARETABLE10 · 30-day cookie · 10% recurring commission
What MOTS-c Is
MOTS-c (mitochondrial open reading frame of the 12S type-c) is a small peptide encoded in mitochondrial DNA. It was first described in 2015 and has been studied in preclinical models for roles in metabolic regulation, insulin sensitivity, and exercise-adaptation pathways. Unlike many commercially available peptides, MOTS-c has a relatively short market history and fewer vendors carry it — making COA verification even more important due to limited independent cross-referencing.5 Checks Before Buying
- Third-party COA (batch-linked): Independent laboratory testing with HPLC and/or MS data and a batch number matching the listing. Given MOTS-c's shorter market history, independent verification is especially important.
- Purity ≥98% with analytical support: Demand visible chromatograms or spectra. A number alone does not confirm what was tested.
- Research-use-only compliance: The vendor should not provide health-outcome framing, metabolic-claim marketing, or dosing guidance. MOTS-c is not FDA-approved for any use.
- Vendor documentation depth: Because MOTS-c is less common than peptides like BPC-157, vendor transparency about sourcing and testing is a stronger signal of legitimacy.
- COA recency: Reports within the last 6-12 months for current inventory. Older reports may not reflect the batch in stock.
Vendor Evaluation Table
| Vendor | COA / Testing Signal | Transparency Score | Risk Level |
|---|---|---|---|
| Peptide Partners | Four-lab roster + contaminant-panel archive | 78/100 · S tier | Low |
| OROS Research | ISO 17025 lab + per-lot testing posture | 75/100 · S tier | Low |
| Pure Peptides | Product-level MZ Biolabs COAs | 73/100 · A tier | Low |
| Crush Research | Four named labs + multi-vial methodology claim | 70/100 · A tier | Medium |
| Kimera Chems | Live COA archive + ISO 17025 lab partner signal | 70/100 · A tier | Medium |
| Elite Research USA | Per-product COAs + three named labs | 70/100 · A tier | Medium |
Seed evaluation from Matt's Reptides intake. Each claim should be re-verified against primary sources before final publication.
Red Flags That Mean Walk Away
Avoid any MOTS-c vendor that: markets with metabolic-outcome claims (weight loss, insulin sensitivity improvements, exercise performance), provides dosing guidance or injection protocols, sells through peer marketplaces (eBay, social media DMs), cannot provide a COA, uses generic lab certificates or self-issued testing documents, or prices significantly below the market average. MOTS-c is less widely tested than other research peptides — limited independent verification means extra buyer diligence is warranted.Frequently Asked Questions
What is MOTS-c used for in research?
In preclinical research, MOTS-c has been studied for its role in metabolic regulation, including insulin sensitivity, exercise adaptation, and age-related metabolic changes. It is a mitochondrial-derived peptide — a class of compounds encoded in mitochondrial DNA rather than nuclear DNA. This page does not recommend or support any use in humans.
Has MOTS-c been FDA-approved?
No. MOTS-c is not FDA-approved for any indication. It is available in the research market as a chemical for laboratory investigation. Products sold by research vendors are not equivalent to any FDA-approved pharmaceutical and should not be conflated with prescription medications.
Why are there fewer MOTS-c vendors compared to BPC-157?
MOTS-c was first described in 2015 and has a shorter commercial history than peptides like BPC-157 or TB-500. Fewer vendors carry it, and fewer independent tests are available for cross-reference. This makes COA verification more important — with fewer data points, each vendor's documentation carries more weight.
How do I verify a MOTS-c COA?
A legitimate COA should come from an ISO-accredited independent laboratory, include batch/lot identification, show HPLC or MS data (chromatograms or spectra), and be dated. Verify the laboratory exists independently through a web search. The report should reference MOTS-c acetate specifically, not just 'peptide' in the compound field.
Related Pages
Peptide Vendor Rankings → · How to Read a COA → · Our Evaluation Methodology →
Verification Notes for MOTS-c for Sale — Buyer Guide 2026
This file is reviewed as part of the The Peptide Reviewer documentation system, which means the page is not judged by headline confidence alone. The desk checks whether the claim has a date, whether the source can be opened by a reader, whether commercial language is separated from editorial scoring, and whether a medical or regulatory boundary is visible before the reader reaches any vendor context.
For mots c for sale, the practical standard is source literacy. A reader should be able to trace the page back to primary records, compare those records with the current vendor or compound claim, and see what the page does not prove. If a vendor changes a COA, removes a lab report, edits a product page, or adds health-outcome language after this review date, the conclusion can change. That is why this publication keeps source dates, correction rules, and reviewer scope close to the article body instead of hiding them in a footer.
The editorial team uses the same baseline checks across peptide vendor reviews, compound explainers, comparison pages, trust pages, and author pages. First, the page must identify the entity or topic clearly. Second, it must point readers toward primary-source verification. Third, it must avoid personal-use instructions and medical recommendations. Fourth, it must disclose when affiliate economics could exist and state that payment does not change scoring, inclusion, risk labels, or rank order.
When the page discusses a compound, the review separates published research context from research-market product claims. Published studies, trial records, or regulatory documents can describe a molecule, but they do not verify a private vendor batch. When the page discusses a vendor, the review separates a vendor's public marketing from documentation that can be checked, including batch-linked certificates, lab identity, source dates, claims language, and correction history.
Readers should treat this file as an audit trail, not a shortcut. The safest way to use it is to open the listed sources, confirm the current date on the vendor or regulatory record, and compare that source with the page summary. If the source and summary disagree, the source wins until the page is corrected. If the source cannot be found, the claim should be treated as unverified.
This added review note also gives crawlers and readers the same context that the editors use internally: what kind of evidence matters, which trust pages govern the file, who owns the review boundary, and where a correction should start. That matters most on author, policy, and directory pages because those pages can look thin even when they carry important E-E-A-T signals. The added context makes the page auditable without turning it into a new article.
- PubMed for published biomedical literature and review context.
- ClinicalTrials.gov for registered trial status and study records.
- FDA for approval status, warning letters, labeling, and regulatory context.
Frequently Asked Questions
How should I verify this page?
Start with the date, then open the primary source rather than relying on a summary. For medical or regulatory context, check PubMed, ClinicalTrials.gov, and FDA records. For vendor context, check the live vendor page, the batch-linked COA, the named lab, and any archived claim record.
Does this page provide medical advice?
No. The Peptide Reviewer publishes editorial source checks and market-transparency reviews. It does not provide treatment advice, dosing protocols, cycles, stacks, injection instructions, reconstitution guidance, diagnosis help, or personal-use recommendations.
Can affiliate relationships change the conclusion?
No. Affiliate relationships, sponsored links, and referral economics do not change scoring, inclusion, rank position, risk labels, author attribution, or medical-review status. Any paid link must be disclosed before the link and marked with sponsored nofollow attributes.
What happens if a source changes?
The page should be updated through the corrections process. A new COA, a changed vendor claim, an FDA update, or a corrected trial record can change the page. Until that update is made, readers should trust the current primary source over the older summary.
Related Standards
Methodology → · Editorial Standards → · Medical Review Policy → · Corrections Policy → · Affiliate Disclosure →